Repurposing the antihistamine cyproheptadine for osteoarthritis: nothing to sneeze at.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41178714.
- Also identified by DOI 10.1172/JCI197144 and PMC identifier 12578381.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Osteoarthritis (OA) is a highly prevalent and painful joint disease in desperate need of disease-modifying therapeutics. Decline in the activity of the Forkhead box O (FOXO) family of transcriptional regulators in articular chondrocytes may contribute to the development of OA. In a study in this issue of the JCI, Kurakazu et al. screened compounds for FOXO activators and discovered that the antihistamine cyproheptadine activated FOXO3 through inhibition of the histamine H1 receptor. Cyproheptadine modulated the activity of OA-relevant pathways and reduced the severity of joint damage and pain behavior in a mouse model of OA, thus showing potential for development as a disease-modifying OA drug.
Medical subject headings
- Osteoarthritis
- Cyproheptadine
- Drug Repositioning
- Histamine H1 Antagonists